OnkoSight AdvancedTM for Plasma Cell Myeloma

Plasma cell myeloma is a clonal late B-cell disorder in which malignant plasma cells expand and accumulate in the bone marrow (BM) resulting in cytopenias, bone resorption (lytic bone lesions), and production of serum monoclonal protein.

The diagnosis and sub-classification of the various plasma cell neoplasms depend on the correlation of radiologic imaging data (bone lesions) and laboratory data (M-protein type and amount) with morphologic, cytogenetic, phenotypic, and molecular findings.

OnkoSight AdvancedTM offers simultaneous detection of somatic gene mutations and genome-wide copy number alterations (CNAs), ranging from single-gene changes to entire chromosome aberrations. OnkoSight AdvancedTM NGS helps provide a more detailed evaluation of multiple myeloma genetics for further risk categorization. Furthermore, may help identify additional abnormalities that may be of prognostic and/or therapeutic value.

Test Information

TL67-3 (PB/BM)
TL68-1 (FFPE)


*The Cancer Genomics Laboratory at GenPath® will require samples with >50% tumor content to run the copy number alteration algorithm. Normal findings will not be reported. The Genome-wide Distribution of CNV and SNV sections in CLL and Multiple Myeloma reports will appear only when an alteration is detected. Visit OnkoSight Advanced Karyotyping in CLL and Plasma Cell Myeloma page to learn more.

Specimen Requirements

OnkoSight Advanced for Plasma Cell Myeloma is validated in both FFPE and PB/BM specimens.

Blood specimen – BML – Bone Marrow – Lavender Top

Tissue specimen – BLK – Formalin-fixed, Paraffin-embedded Tissue

GenPath also offers singe-gene testing. Healthcare providers should only panels if each gene or test in the panel is medically necessary.